Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an immunoglobulin presented as a sterile solution for intravenous use. It is used to replace deficient antibodies in patients with primary immunodeficiency diseases and provides passive immunity. GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Panzyga is an immunoglobulin therapy that addresses disorders of the immune system.

- Primary immunodeficiency diseases: provides replacement therapy for missing or low‑producing antibodies. - Secondary immunodeficiency following chemotherapy : supports immune function during cancer treatment. - Post‑exposure prophylaxis for certain viral infections : supplies  the antibodies  that  contribute  to  viral  neutralisation. - Primary  the  t   un  immune  dis  orders  of  the  immune  system  (  e  .g.,  Kawasaki  d  isease  ). -         

The